IL-17A Inhibitors Appear Effective in Treating AS, But Safety Needs Further Study

IL-17A Inhibitors Appear Effective in Treating AS, But Safety Needs Further Study

287341

IL-17A Inhibitors Appear Effective in Treating AS, But Safety Needs Further Study

Medications that block the activity of the pro-inflammatory molecule interleukin-17A (IL-17A) can ease symptoms of ankylosing spondylitis (AS), but further research is needed to evaluate their safety, according to an analysis. These findings were in the study “Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials,” published in the journal Clinical Rheumatology. AS is characterized by inflammation that affects the joints of the spine, leading…

You must be logged in to read/download the full post.